A Study to Assess the Efficacy and Safety of PF-06650833, PF-06651600, and Tofacitinib Alone and in Combination in Active Rheumatoid Arthritis. A 24-Week Randomized, Double-Blind, Parallel Group, Active Comparator, Multicenter Study to Assess the Efficacy and Safety of PF-06650833, PF- 06651600 (Ritlecitinib) and Tofacitinib Alone and in Combination in Participants With Moderately-Severely Active Rheumatoid Arthritis With an Inadequate
Response to Methotrexate.